This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (10)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Pulmonary Diseases  • Chronic Obstructive Pulmonary Disease  • Diagnosis  • Alert me on articles by topic  Social Bookmarking   What's this?

Clinical Applications

S. F. Paul Man, MD; Finlay A. McAlister, MD, MSc; Nick R. Anthonisen, MD, PhD; Don D. Sin, MD, MPH

JAMA. 2003;290:2313-2316.

The presentation of chronic obstructive pulmonary disease (COPD) usually is insidious, and many patients are undiagnosed until the disease is far advanced. Therefore, the early use of spirometry is recommended for anyone who is suspected to have COPD. In the early stages of the disease, the patient is only mildly symptomatic (cough and sputum production). As COPD becomes more advanced, functional impairment in the form of chronic dyspnea occurs and acute exacerbations of symptoms become more frequent, contributing to overall morbidity and mortality. The single most important known causative factor of COPD is cigarette smoking. Smoking cessation remains, therefore, the mainstay of COPD therapy. In patients with advanced disease, symptomatic treatment with the regular use of either short- or long-acting sympathomimetic and/or anticholinergic bronchodilators, singly or in combination, should be added to smoking cessation and influenza and pneumococcal vaccination therapies. An inhaled corticosteroid, either alone or more commonly in combination with a long-acting bronchodilator, can further reduce exacerbations and improve the health status of these patients. Furthermore, patients with severe COPD, particularly those who are debilitated, should be considered for pulmonary rehabilitation because these programs have been proven useful in maintaining, or in some cases improving, health status for these patients. Finally, correction of resting arterial hypoxemia with oxygen therapy for more than 15 h/d prolongs survival of COPD patients for those with a resting PaO₂ lower than 55 to 60 mm Hg.

Author Affiliations: Divisions of Pulmonary Medicine (Drs Man and Sin) and General Medicine (Dr McAlister), University of Alberta, Edmonton; Institute of Health Economics (Drs McAlister and Sin), Edmonton, Alberta; and Department of Medicine, University of Manitoba, Winnipeg (Dr Anthonisen)

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLES

Contemporary Management of Chronic Obstructive Pulmonary Disease: Scientific Review
Don D. Sin, Finlay A. McAlister, S. F. Paul Man, and Nick R. Anthonisen
JAMA. 2003;290(17):2301-2312.
ABSTRACT | FULL TEXT  

Chronic Obstructive Pulmonary Disease
Sharon Parmet, Cassio Lynm, and Richard M. Glass
JAMA. 2003;290(17):2362.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Calverley et al.
NEJM 2007;356:775-789.
ABSTRACT | FULL TEXT  

Comparison of lidocaine and bronchodilator inhalation treatments for cough suppression in patients with chronic obstructive pulmonary disease
Chong et al.
Emerg. Med. J. 2005;22:429-432.
ABSTRACT | FULL TEXT  

Effects of Corticosteroids on Systemic Inflammation in Chronic Obstructive Pulmonary Disease
Man and Sin
Proc Am Thorac Soc 2005;2:78-82.
ABSTRACT | FULL TEXT